---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-057861"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:40:46.700739+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q4 net loss $52.7M, FY2021 net loss $187.1M; RAS pipeline advances

## Summary
- Cash, cash equivalents and marketable securities $577.1M at Dec 31, 2021 vs $440.7M at Dec 31, 2020.
- Total revenue $9.5M Q4 2021 vs $8.8M Q4 2020; FY2021 $29.4M vs $43.0M FY2020 (incl. $8.5M non-cash adjustment).
- Net loss $52.7M Q4 2021 vs $34.2M Q4 2020; FY2021 $187.1M vs $108.2M FY2020.
- Full year 2022 GAAP net loss guidance $260M-$290M; stock-based comp $35M-$40M.
- RMC-4630+sotorasib Phase 2 first patient dosed; IND plans: RMC-6236 & RMC-6291 H1 2022, RMC-9805 H1 2023, RMC-8839 H2 2023.

## SEC filing metadata
- accession: 0001193125-22-057861
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000119312522057861/0001193125-22-057861-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000119312522057861/d214686d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-057861
- JSON: https://secwatch.observer/filing/0001193125-22-057861.json
- Plain text: https://secwatch.observer/filing/0001193125-22-057861.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.